No quarterly revenue total was found in OCEAN BIOMEDICAL, INC.'s SEC filings.
Ocean Biomedical, Inc. (OCEA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-8.24M
-163.4% vs year-ago quarter
Operating cash flow
$-356,000
+26.6% vs year-ago quarter
Free cash flow
—
EPS
$-0.09
-118.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
232.37M
+40.0% vs prior quarter
Net cash
$-2.20M
Q4 FY2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OCEA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869974
- Former names
- Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2025 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
Q2 FY2024 Jun 30, 2024 |
Q1 FY2024 Mar 31, 2024 |
|---|---|---|---|---|---|
| Operating income | -$958,000 | -$1.8M | -$768,000 | -$682,000 | -$595,000 |
| Net income | -$8.2M | -$1.5M | -$3.7M | -$17.2M | $13.0M |
| Diluted EPS | -$0.09 | -$0.06 | -$0.13 | -$0.63 | $0.48 |
| Operating cash flow | -$356,000 | -$2.4M | -$957,000 | -$290,000 | -$485,000 |
| Total assets | $1.6M | $902,000 | $1.1M | $1.9M | $2.9M |
| Total liabilities | $94.0M | $98.5M | $97.4M | $94.6M | $78.7M |
| Stockholders' equity | -$92.4M | -$97.6M | -$96.3M | -$92.7M | -$75.8M |
| Cash and investments | $800,000 | $200,000 | $200,000 | $200,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Officer or director change, Other events
|
Aug 5, 2025 | Jul 31, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 23, 2025 | Jul 17, 2025 |
| 8-K |
Current report
Agreement ended
|
Jul 16, 2025 | Jul 10, 2025 |
| 8-K |
Current report
Agreement ended
|
Jun 13, 2025 | Jun 12, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 10-K/A | Amended annual report | Apr 29, 2025 | Dec 31, 2024 |
All 255 Ocean Biomedical, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.